Crohn’s disease, similar to Johne’s disease (a Mycobacterium avium subsp. paratuberculosis-caused inflammatory bowel disease in ruminants and primates), is an inflammatory bowel disease with suspected mycobacterial etiology (1). The disease emerged perceptibly in Western Europe and North America in the late 1940s and early 1950s. The incidence then increased progressively on both continents to a level which in some areas, such as northeast Scotland (11.6/100,000 per year), now approaches that of an epidemic (4). Granulomas and lymph node alteration in Crohn’s disease patients resemble those of tuberculosis, leprosy, sarcoidosis, and bovine paratuberculosis (3). The latter has been suggested as a reservoir for epidemiologic transmission of the microorganism through contaminated dairy and meat products and possibly even in water (5).
In this study, we analyzed the humoral immune responses of Crohn’s disease patients compared with those of age-matched controls against two recombinant clones of M. avium subsp. paratuberculosis. The recombinant clones, designated p35 and p36 and expressing 35- and 36-kDa proteins, respectively, were identified from a previously constructed expression genomic library of M. avium subsp. paratuberculosis that was screened by Western blotting against rabbit hyperimmune anti-M. avium subsp. paratuberculosis antibodies (2). A total of 110 human serum specimens, consisting of samples from 61 Crohn’s disease patients and 47 controls (35 volunteers with no history or symptoms of gastrointestinal tract disorder and 12 individuals diagnosed with ulcerative colitis) were analyzed by Western blotting (5). The participants who donated the sera used in this study were free of tuberculosis, leprosy, and/or had not received the Mycobacterium bovis BCG vaccine. As shown in Table 1, of the 61 Crohn’s disease-positive serum samples tested, 48 (79%) reacted with p35, 56 (92%) reacted with p36, 47 (77%) reacted with both antigens, and 57 (93%) reacted with either antigen. As expected, a small portion of Crohn’s disease-positive serum specimens, four (7%), did not react with either antigen. Of the 35 serum samples from healthy controls, 5 (14%) reacted with p35, 4 (11%) reacted with p36, none (0%) reacted with both antigens, and 9 (26%) reacted with either antigen. Of the 12 ulcerative colitis-positive serum specimens, only 1 (8%) reacted with p35 or p36, either individually or combined. The only ulcerative colitis patient who reacted positively with these antigens is under further evaluation for possibility of misdiagnosis. Crohn’s and ulcerative colitis diseases are inseparable at the early stage of infection. Many physicians refer to them as colitis diseases.
TABLE 1.
Reactivities of serum samples from Crohn’s disease patients and controls with p35 and p36 recombinant antigens of M. avium subsp. paratuberculosis
| Antigen(s) | No. (%) of reactive serum samples
from:
|
||
|---|---|---|---|
| Crohn’s disease patients | Ulcerative colitis patients | Controls | |
| p35 | 48 (79) | 1 (8) | 5 (14) |
| p36 | 56 (92) | 1 (8) | 4 (11) |
| p35 and p36 | 47 (77) | 1 (8) | 0 (0) |
| p35 or p36 | 57 (93) | 1 (8) | 9 (26) |
| Total | 61 | 12 | 35 |
These data confirm that there is a statistically significant difference in reactivity between Crohn’s disease-positive serum samples and serum samples from controls (P < 0.001). This ultimately adds more evidence to strengthen the proposed association of Mycobacteria with Crohn’s disease. The data also suggest that there is great potential for using M. avium subsp. paratuberculosis recombinant antigens (p35 and p36) individually or combined in a serologic test for diagnosis and possibly in vaccine development.
Acknowledgments
We would like to thank William Fenster for his work in carrying out the experiments and Anita Shafran for her role in blood specimen collection.
Our thanks are also due to the College of Health and Public Affairs at the University of Central Florida for financial support of this study.
REFERENCES
- 1.Chiodini R J, Van Kruiningen H J, Thayer W R, Coutu J A. Spheroplastic phase of mycobacteria isolated from patients with Crohn’s disease. J Clin Microbiol. 1986;24:357–363. doi: 10.1128/jcm.24.3.357-363.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.El-Zaatari F A K, Naser S A, Engstrand L, et al. Identification and characterization of Mycobacterium paratuberculosis recombinant clones expressed in E. coli. Curr Microbiol. 1994;29:177–184. doi: 10.1007/BF01570760. [DOI] [PubMed] [Google Scholar]
- 3.Graham D Y, Markesich D G, Kalter D C, et al. Mycobacterial aetiology of sarcoidosis. Lancet. 1992;340:52–53. doi: 10.1016/0140-6736(92)92465-r. [DOI] [PubMed] [Google Scholar]
- 4.Kyle J. Crohn’s disease in the northeastern and northern Isles of Scotland: an epidemiological review. Gastroenterology. 1992;103:392–399. doi: 10.1016/0016-5085(92)90826-k. [DOI] [PubMed] [Google Scholar]
- 5.Millar D, Ford J, Sanderson J, Withey S, Tizard M, Doran T, Hermon-Taylor J. IS900 PCR to detect Mycobacterium paratuberculosis in retail supplies of whole pasteurized cows’ milk in England and Wales. Appl Environ Microbiol. 1996;62:3446–3452. doi: 10.1128/aem.62.9.3446-3452.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]